Alzamend Neuro, Inc. financial data

Symbol
ALZN on Nasdaq
Location
3500 Lenox Rd. Ne, Suite 1500, Atlanta, GA
State of incorporation
DE
Fiscal year end
April 30
Latest financial report
10-Q - Q3 2024 - Dec 11, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 449 % -64.7%
Debt-to-equity -276 % -242%
Return On Equity 547 %
Return On Assets -292 % +13.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.43M shares -23.7%
Common Stock, Shares, Outstanding 5.23M shares -19.1%
Entity Public Float 6.7M USD -89.9%
Common Stock, Value, Issued 523 USD -19.2%
Weighted Average Number of Shares Outstanding, Basic 3.53M shares +438%
Weighted Average Number of Shares Outstanding, Diluted 3.53M shares +438%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.61M USD -70.7%
General and Administrative Expense 3.22M USD -48.5%
Costs and Expenses 14.9M USD +20.7%
Operating Income (Loss) -5.83M USD +61.5%
Nonoperating Income (Expense) -19.5K USD -123%
Net Income (Loss) Attributable to Parent -5.9M USD +61.1%
Earnings Per Share, Basic -6.54 USD/shares +79.7%
Earnings Per Share, Diluted -6.54 USD/shares +79.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.09M USD +1946%
Assets, Current 4.77M USD +510%
Property, Plant and Equipment, Net 241K USD +19.5%
Assets 5.01M USD +409%
Accounts Payable, Current 1.25M USD -65.8%
Liabilities, Current 3.83M USD +44.8%
Liabilities 1.25M USD -65.8%
Retained Earnings (Accumulated Deficit) -56.4M USD -11.7%
Stockholders' Equity Attributable to Parent 3.75M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.75M USD
Liabilities and Equity 5.01M USD +409%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.06M USD +68%
Net Cash Provided by (Used in) Financing Activities 1.96M USD
Net Cash Provided by (Used in) Investing Activities -90K USD +38.9%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 5.23M shares -19.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.09M USD +1946%
Deferred Tax Assets, Valuation Allowance 15.8M USD +45.8%
Deferred Tax Assets, Gross 15.8M USD +45.9%
Depreciation 12.7K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 10.8M USD +57.4%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 60.2M USD -4.05%
Share-based Payment Arrangement, Expense 81.3K USD -53.8%
Interest Expense 19.5K USD +123%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%